All Oncology News

Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.

Early complete clearance of ctDNA was linked with clinical responses to daraxonrasib in RAS-mutant advanced non–small cell lung cancer.

A retrospective analysis showed higher response rate for cabozantinib/nivolumab vs. lenvatinib/pembrolizumab in advanced RCC.

First-line tiragolumab plus atezolizumab did not improve PFS and OS vs atezolizumab alone in PD-L1–high, unresectable or metastatic NSCLC.

Bria-IMT plus checkpoint inhibition showed a manageable safety profile and activity in metastatic breast cancer.

The majority of patients with prostate cancer treated with an enzalutamide or leuprolide acetate regimen recovered their testosterone levels.

Treatment with 6.5 mg/kg of tegavivint was associated with primarily grade 1/2 TRAEs in patients with advanced hepatocellular carcinoma.

Patients with mCRPC enrolled in the phase 3 TALAPRO-2 trial harboring TMPRSS2-ERG fusions in ctDNA had a distinct tumor molecular profile vs those without.

China’s NMPA approved ivonescimab for the first-line treatment of PD-L1–positive advanced non–small cell lung cancer.

Zongertinib provided clinical benefit in previously treated advanced non–small cell lung cancer harboring HER2 mutations.

Linvoseltamab earned EC approval for relapsed/refractory multiple myeloma after at least 3 prior lines of therapy.

Jason A. Mouabbi, MD, discusses the use of ctDNA to enhance early detection of ESR1 or other resistance mutations in HR-positive breast cancer.

Dana-Farber Cancer Institute highlights research being presented at the 2025 AACR Annual Meeting.

Talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide in patients with mCRPC with or without AR alterations.

Olaparib plus pembrolizumab was safe and effective in HRR gene–mutated and/or HRD-positive advanced tumors.

Penpulimab plus chemotherapy improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma.

Interim data from a phase 2 study support the potential of TARA-002 as an intravesical immunotherapy in high-risk NMIBC.

Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.

Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.

Neoadjuvant mitomycin C improved 18-month recurrence-free survival and demonstrated favorable safety in non–muscle-invasive bladder cancer.

The addition of disitamab vedotin to BCG demonstrated high CR rates in HER2-expressing, high-risk NMIBC.

Nogapendekin alfa inbakicept demonstrated sustained CR rates in patients with high-risk BCG-unresponsive NMIBC.

UGN-102 elicits robust responses with acceptable tolerability in recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

No complete or partial pathologic responses were achieved with neoadjuvant niraparib in patients with DDR-deficient prostate cancer following surgery.

Enfortumab vedotin plus pembrolizumab followed by surgery led to high CR rates in advanced urothelial cancer.

TAR-200 showed promising results in treating patients with BCG-unresponsive, high-risk NMIBC, achieving an 82.4% complete response rate.

Cretostimogene grenadenorepvec generated complete responses in patients with high-risk BCG-unresponsive NMIBC and CIS with or without Ta/T1 tumors.

TAR-200 produced durable disease-free survival in BCG-unresponsive, papillary-only, high-risk non–muscle-invasive bladder cancer.

Sasanlimab plus BCG significantly improved EFS vs BCG alone in high-risk non–muscle-invasive bladder cancer.